Insider Buying Stocks
SGP is part of our Insider Buying Stocks list, indicating stock insiders are buying the stock.
SPYGLASS PHARMA INC (SGP) Stock Price & Overview
NASDAQ:SGP • US85220G1094
Current stock price
23 USD
-0.65 (-2.75%)
At close:
23 USD
0 (0%)
After Hours:
The current stock price of SGP is 23 USD. Today SGP is down by -2.75%. In the past month the price decreased by -1.58%.
SGP Key Statistics
1-Month Range20.15 - 27.225
Current SGP stock price positioned within its 1-month range.
- Market Cap
- 768.89M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -2.50
- Dividend Yield
- N/A
SGP Stock Performance
Today
-2.75%
1 Week
-5.93%
1 Month
-1.58%
3 Months
N/A
Longer-term
6 Months N/A
1 Year N/A
2 Years N/A
3 Years N/A
5 Years N/A
10 Years N/A
SGP Stock Chart
SGP Stock Screens
SGP currently appears in the following ChartMill screener lists.
SGP Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to SGP.
Chartmill TA Rating
Chartmill Setup Rating
SGP Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to SGP. No worries on liquidiy or solvency for SGP as it has an excellent financial health rating, but there are worries on the profitability.
Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
SGP Earnings
Next Earnings DateN/A
Last Earnings DateMar 26, 2026
PeriodQ4 / 2025
EPS Reported
Revenue Reported
EPS Surprise %
Revenue Surprise %
SGP Forecast & Estimates
9 analysts have analysed SGP and the average price target is 45.9 USD. This implies a price increase of 99.57% is expected in the next year compared to the current price of 23.
Analysts
Analysts88.89
Price Target45.9 (99.57%)
EPS Next Y8.04%
Revenue Next YearN/A
SGP Financial Highlights
Over the last trailing twelve months SGP reported a non-GAAP Earnings per Share(EPS) of -2.5. The EPS decreased by -36.71% compared to the year before.
Income Statements
Revenue(TTM)N/A
Net Income(TTM)-79.74M
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -68.82% | ||
| ROE | -75.44% | ||
| Debt/Equity | 0 |
Chartmill High Growth Momentum
EPS Q2Q%-36.71%
Sales Q2Q%N/A
EPS 1Y (TTM)-36.71%
Revenue 1Y (TTM)N/A
SGP Ownership
Ownership
Inst Owners76.68%
Shares33.43M
Float32.25M
Ins Owners3.53%
Short Float %3.22%
Short Ratio9.1
SGP Industry Overview
SGP operates in the Pharmaceuticals sub-industry within the Health Care sector. This group contains 135 stocks and is scored by ChartMill on both price strength and growth momentum.
Industry Strength Score
65/100
Composite price performance score based on 3, 6, and 12-month returns, with more weight on recent trends.
Industry Growth Score
17/100
Composite growth score based on earnings growth, revenue growth, and profitability across the sub-industry.
Relative Performance
Each rank shows how many other sub-industries were outperformed over that timeframe.
1 Month Rank
62%
Outperformed 62% of sub-industries
3 Month Rank
47%
Outperformed 47% of sub-industries
6 Month Rank
37%
Outperformed 37% of sub-industries
Industry Fundamentals & Breadth
- Members
- 135
- New Highs
- 4.4%
- New Lows
- 4.4%
- Average ROE
- 50.6%
- Average Profit Margin
- 27.8%
- Average Operating Margin
- 37.5%
- Average P/E
- 25.4
- Average Fwd P/E
- 20.0
- Average Debt/Equity
- 1.2
SGP Competitors/Peers
The largest stocks on the US markets in the "Pharmaceuticals" sub-industry
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 25 | 825.773B | ||
| JNJ | JOHNSON & JOHNSON | 17.96 | 548.657B | ||
| MRK | MERCK & CO. INC. | 21.61 | 271.761B | ||
| PFE | PFIZER INC | 8.86 | 150.628B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 9.2 | 118.952B | ||
| ZTS | ZOETIS INC | 16.49 | 49.054B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.59 | 28.582B | ||
| VTRS | VIATRIS INC | 5.94 | 17.257B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 21.05 | 11.061B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 9.463B | ||
| TERN | TERNS PHARMACEUTICALS INC | N/A | 6.11B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 5.955B | ||
| CORT | CORCEPT THERAPEUTICS INC | 85.91 | 4.959B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About SGP
Company Profile
SpyGlass Pharma Inc is a US-based company operating in Pharmaceuticals industry. The company is headquartered in Aliso Viejo, California and currently employs 65 full-time employees. The company went IPO on 2026-02-06. SpyGlass Pharma Inc is a late-stage biopharmaceutical company focused in the development of the treatment paradigm for patients living with chronic eye conditions through long-acting, sustained drug delivery of approved medicines. The firm develops a non-bioerodible drug delivery technology, designed to be used with various well-established, approved medicines, including bimatoprost and other small molecules, providing flexibility to potentially treat a range of conditions in the front and back of the eye. Its lead product, the Bimatoprost Drug Pad-IOL System (BIM-IOL System) is designed to be implanted during routine cataract surgery to reduce elevated intraocular pressure (IOP) in patients who have either open-angle glaucoma or ocular hypertension.
Company Info
IPO: 2026-02-06
SPYGLASS PHARMA INC
27081 Aliso Creek Road, Suite 125
Aliso Viejo CALIFORNIA US
Employees: 65
Phone: 13026587581
SPYGLASS PHARMA INC / SGP FAQ
What does SGP do?
SpyGlass Pharma Inc is a US-based company operating in Pharmaceuticals industry. The company is headquartered in Aliso Viejo, California and currently employs 65 full-time employees. The company went IPO on 2026-02-06. SpyGlass Pharma Inc is a late-stage biopharmaceutical company focused in the development of the treatment paradigm for patients living with chronic eye conditions through long-acting, sustained drug delivery of approved medicines. The firm develops a non-bioerodible drug delivery technology, designed to be used with various well-established, approved medicines, including bimatoprost and other small molecules, providing flexibility to potentially treat a range of conditions in the front and back of the eye. Its lead product, the Bimatoprost Drug Pad-IOL System (BIM-IOL System) is designed to be implanted during routine cataract surgery to reduce elevated intraocular pressure (IOP) in patients who have either open-angle glaucoma or ocular hypertension.
Can you provide the latest stock price for SPYGLASS PHARMA INC?
The current stock price of SGP is 23 USD. The price decreased by -2.75% in the last trading session.
What is the dividend status of SPYGLASS PHARMA INC?
SGP does not pay a dividend.
What is the ChartMill technical and fundamental rating of SGP stock?
SGP has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
On which exchange is SGP stock listed?
SGP stock is listed on the Nasdaq exchange.
What is the GICS sector and industry of SGP stock?
SPYGLASS PHARMA INC (SGP) operates in the Health Care sector and the Pharmaceuticals industry.
What is the outstanding short interest for SPYGLASS PHARMA INC?
The outstanding short interest for SPYGLASS PHARMA INC (SGP) is 3.22% of its float.